PharmaBlock Sciences (Nanjing), Inc. (SHE:300725)
China · Delayed Price · Currency is CNY 40.01
-0.69 (-1.70%)
Apr 29, 2026, 3:04 PM CST
SHE:300725 Revenue
PharmaBlock Sciences (Nanjing) had revenue of 508.03M CNY in the quarter ending March 31, 2026, with 11.65% growth. This brings the company's revenue in the last twelve months to 2.03B, up 14.80% year-over-year. In the year 2025, PharmaBlock Sciences (Nanjing) had annual revenue of 1.97B with 16.93% growth.
Revenue (ttm)
2.03B
Revenue Growth
+14.80%
P/S Ratio
4.68
Revenue / Employee
844.79K
Employees
2,400
Market Cap
9.48B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.97B | 285.86M | 16.93% |
| Dec 31, 2024 | 1.69B | -36.58M | -2.12% |
| Dec 31, 2023 | 1.73B | 130.50M | 8.18% |
| Jan 1, 2023 | 1.59B | 393.07M | 32.71% |
| Dec 31, 2021 | 1.20B | 179.40M | 17.55% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shenzhen Neptunus Bioengineering | 27.28B |
| Harbin Pharmaceutical Group | 15.96B |
| Chongqing Taiji Industry(Group) Co.,Ltd | 10.50B |
| North China Pharmaceutical Company.Ltd | 8.82B |
| Shandong Lukang Pharmaceutical | 5.71B |
| Zhejiang Xianju Pharmaceutical | 3.76B |
| Jiuzhitang | 2.23B |
| HARBIN GLORIA PHARMACEUTICALS Co., LTD | 2.14B |